Clinical trials: Bundibugyo Virus Disease
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age
The main objective of this trial is to evaluate the safety of mRNA-1469
- Trial name
- NCT07919197
- Testing
- mRNA-1469
- Where
- Uganda
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
- Trial name
- NCT07737717
- Testing
- mRNA-1469
- Where
- 3 sites in Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola, Bundibugyo Virus Disease (BVD)
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
The BRAVO study (Bundibugyo: Respondre Avec la Vaccination, "On est ensemble") was developed in response to the 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC).
- Trial name
- BRAVO (NCT07903350)
- Testing
- ERVEBO Vaccination
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden